PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34099830-1	2021	Recent studies suggested that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, developed for the treatment of chronic lymphocytic leukemia, may prevent NLRP3 inflammasome activation in macrophages, IL-1beta secretion and subsequent development of inflammation and organ fibrosis.	ibrutinib	30-39	NLR family pyrin domain containing 3	Homo sapiens	156-161